Ligand Pharmaceuticals, Inc. (LGNZZ)
LGNZZ Stock Price Chart
Explore Ligand Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze LGNZZ price movements and trends.
LGNZZ Company Profile
Discover essential business fundamentals and corporate details for Ligand Pharmaceuticals, Inc. (LGNZZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
16 Jun 2004
Employees
68.00
Website
https://www.ligand.comCEO
Todd C. Davis
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
LGNZZ Financial Timeline
Browse a chronological timeline of Ligand Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
Upcoming earnings on 4 Aug 2025
Revenue estimate is $43.87M.
Earnings released on 8 May 2025
EPS came in at -$2.21 falling short of the estimated $1.21 by -282.81%, while revenue for the quarter reached $45.33M, beating expectations by +2.32%.
Earnings released on 27 Feb 2025
EPS came in at -$1.70, while revenue for the quarter reached $42.81M, beating expectations by +9.70%.
Earnings released on 7 Nov 2024
EPS came in at -$0.39, while revenue for the quarter reached $51.81M, beating expectations by +32.81%.
Earnings released on 6 Aug 2024
EPS came in at -$2.88, while revenue for the quarter reached $41.53M.
Earnings released on 7 May 2024
EPS came in at $4.75, while revenue for the quarter reached $30.98M.
Earnings released on 14 Mar 2024
EPS came in at $1.03, while revenue for the quarter reached $28.10M.
Earnings released on 27 Feb 2024
EPS came in at -$0.59, while revenue for the quarter reached $32.87M.
Earnings released on 9 Aug 2023
EPS came in at $0.13, while revenue for the quarter reached $26.37M.
Earnings released on 8 May 2023
EPS came in at $2.33, while revenue for the quarter reached $43.98M.
Earnings released on 28 Feb 2023
EPS came in at -$1.04, while revenue for the quarter reached $50.38M.
Earnings released on 8 Nov 2022
EPS came in at $0.02, while revenue for the quarter reached $66.09M.
Earnings released on 9 Aug 2022
EPS came in at -$0.05, while revenue for the quarter reached $57.42M.
Earnings released on 30 Mar 2022
EPS came in at -$0.91, while revenue for the quarter reached $45.69M.
Earnings released on 28 Feb 2022
EPS came in at -$0.30, while revenue for the quarter reached $72.47M.
Earnings released on 29 Sept 2021
EPS came in at $0.80, while revenue for the quarter reached $64.83M.
Earnings released on 2 Aug 2021
EPS came in at $1.79, while revenue for the quarter reached $84.68M.
Earnings released on 30 Mar 2021
EPS came in at $1.05, while revenue for the quarter reached $55.15M.
Earnings released on 24 Feb 2021
EPS came in at -$0.08, while revenue for the quarter reached $186.42M.
LGNZZ Stock Performance
Access detailed LGNZZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.